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Abstract
Background: Despite progression in treatment of gastric cancer, prognosis of patients remains poor, in part due
to the low rate of diagnosis during its early stages. This paradigm implies the necessity to identify molecular
biomarkers for early gastric cancer diagnosis, as well as for disease monitoring, thus contributing to the
development of new therapeutic approaches. In a previous study, performed by array-Comparative Genomic
Hybridization, we described for the first time in literature recurrent amplification of RTEL1 and ABCA13 genes in
gastric cancer. Thus, the aim of the present study was to validate recurrent amplification of RTEL1 and ABCA13
genes and associate CNV status with clinicopathological data.
Findings: Results showed RTEL1 and ABCA13 amplification in 38 % of samples. Statistical analysis demonstrated
that RTEL amplification is more common in older patients and more associated with intestinal type and ABCA13
amplification increases the risk of lymph node metastasis and is more common in men. Co-amplification of these
genes showed a significant association with advanced staging.
Conclusions: aCGH is a very useful tool for investigating novel genes associated with carcinogenesis and RTEL1
amplification may be important for the development of gastric cancer in older patients, besides being a probable
event contributing for chromosomal instability in intestinal gastric carcinogenesis. ABCA13 amplification may have
age-specific function and could be considered a useful marker for predicting lymph node metastasis in resected
gastric cancer patients in early stage. Lastly, RTEL1 and ABCA13 synergistic effect may be considered as a putative
marker for advanced staging in gastric cancer patients.
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Background
Gastric cancer is the fifth most frequent type of cancer
and the third cause of cancer mortality worldwide [1].
The estimate for Brazil (2016 and 2017) indicates the
occurrence of about 600,000 new cases of cancer. Except
for non-melanoma skin cancer (approximately 180,000
new cases), there will be about 420,000 new cases of
cancer. Among all different types of cancer that affect
humans, gastric cancer, excluding non-melanoma skin
cancer, ranks fourth as the most frequent tumor type in
men and fifth in women [2]. In the Northern Brazil, ex-
cluding non-melanoma skin cancer, gastric cancer is the
second most frequent cancer among men and the fourth
among women [2].
The incidence rate of gastric cancer have decreased
overall in recent years, however, it remains the leading
cause of cancer-related mortality in developing countries
[3]. Despite progression in treatment of advanced gastric
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cancer, the prognosis of gastric cancer patients remains
poor, in part due to the low rate of diagnosis during its
early stages [4]. This paradigm implies the necessity to
search and identify molecular biomarkers for early gas-
tric cancer diagnosis, as well as for disease monitoring,
thus contributing to the development of new therapeutic
approaches [5].
With regard to gastric cancer treatment, with the ex-
ception of trastuzumab (therapy based on the overex-
pression of HER2 protein and/or the amplification of its
gene ERBB2), chemotherapy of localized and advanced
gastric cancer still does not consider genotypic tumor
characteristics. This implies that part of the patients, if
not the majority, receives medical treatment with sub-
optimal or even lacking efficacy [6, 7].
Recently, numerous studies have investigated the mole-
cular basis of gastric cancer involving the alteration of
pathogenesis, including the mechanisms of invasion and
metastasis. With the development of modern technologies,
various novel biomarkers had been identified that appear
to possess diagnostic and prognostic value [4]. Among the
types of biomarkers, copy number variation (CNV) in key
genes has been found in gastric cancer [8–10].
In a previous study, preformed by array-Comparative
Genomic Hybridization (aCGH), we observed many gen-
omic alterations in 22 patients and described for the first
time in literature the recurrent amplification of RTEL1
(Regulator of Telomere Length 1) gene, located on
20q13.33 (OMIM: 608833), and ABCA13 (ATP-Binding
Cassette, Sub-Family A, Member 13) gene, located on
7p12.3 (OMIM: 607807), in gastric adenocarcinoma,
with a frequency of 50 and 23 %, respectively [11].
RTEL1 is an essential helicase that has been demon-
strated to be required for the maintenance of telomere
length and genomic stability. Thus, RTEL1 dysfunction
is dramatically mutagenic and plays an important role in
tumor initiation and progression [12, 13].
ABCA13 gene is a member of ABC (ATP-binding cas-
sette) family of transporters that plays a crucial role in
the development of resistance by the efflux of anticancer
agents outside of cancer cells [14]. Recently, several
studies have associated overexpression of ABCA13 with
poor prognosis of cancer [15, 16].
Therefore, the aim of the present study was to validate
the recurrent amplification of RTEL1 and ABCA13 genes
observed previously by aCGH and associate CNV status
with clinicopathological data of patients.
It is noteworthy to mention that we have chosen
RTEL1 gene due to high frequency of its amplification in
gastric adenocarcinoma samples observed by aCGH. On
the other hand, ABCA13 was chosen due to its signifi-
cant association with serosal extravasation. For both
genes, we have also taken into account the agreement of
results with data present in literature.
CNV analysis demonstrated a significant association be-
tween gene amplification and co-amplification with clinico-
pathological data of patients with gastric adenocarcinoma.
Results
RTEL1 gene amplification was observed in 38 % of sam-
ples (Fig. 1). Statistical analysis showed that this amplifica-
tion is 2.6 times more common in patients older than
50 years (p = 0.045; 95 % CI = 1.011–5.128) and 2.3 times
more associated with intestinal type (p = 0.034; 95 % CI =
1.057–6.3) (Table 1).
ABCA13 gene amplification was also observed in 38 %
of samples (Fig. 2). Statistical analysis showed that
ABCA13 amplification increases 3 times the risk of
lymph node metastasis (p = 0.033; 95 % CI = 1.057–
9.018). Additionally, this amplification is 4 times more
common in men (p = 0.003; 95 % CI = 1.526–9.851) and
demonstrated an inconclusive association with intestinal
type (p = 0.079) (Table 1).
Synergistic effect of these two amplifications was also
evaluated. The results showed that RTEL1 and ABCA13
amplification in the same patient was 3 times more asso-
ciated with advanced stage (III and IV) (p = 0.05; 95 %
CI = 0.958–10.037) (Table 1).
Subcategorization of samples into intestinal and dif-
fuse types did not result in any significant clinicopatho-
logical association.
It is important to note that 51 % (23/45) and 21 %
(10/47) of ABCA13 and RTEL1 amplifications, respect-
ively, were high-level amplifications (≥5 copies), but sub-
division of samples into high-level amplifications and
other amplifications (3 and 4 copies) or high-level ampli-
fications and all other (1, 2, 3 and 4 copies) did not re-
sult in any significant clinicopathological association.
Regarding oral squamous cell carcinoma, we observed
30 and 25 % of RTEL1 and ABCA13 amplification, re-
spectively, but the presence of amplification was not statis-
tically associated with clinicopathological data of patients.
Discussion
High amplification frequencies observed in the present
study corroborate with the previous study performed by
aCGH, indicating that this technique is useful to investi-
gate CNV and find novel genes associated with diseases,
even with a low number of cases.
The statistical association of ABCA13 with serosal ex-
travasation [11] was not confirmed by real time PCR
and new significant associations were observed, includ-
ing for RTEL1 gene. This discrepancy is probably due to
differences in sample size of each investigation.
The region 20q, where RTEL1 gene is located, is amp-
lified in several types of cancer [17–19], but we were the
first group to describe RTEL1 amplification in gastric
cancer [11].
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Rtel1 is an essential helicase for telomere maintenance
and the regulation of homologous recombination (HR)
[12]. HR is one of the major pathways to maintain gen-
omic stability and is involved in the repair of complex
DNA damage, DSBs, interstrand crosslinks and DNA
gaps. Thus, upregulated Rtel1 function might prevent
HR when it is needed as a legitimate means for repair,
leading to malfunction of repair system [20].
Another hypothesis is that the excessive activity of
Rtel1 would increase Rtel1 helicase activity, leading to
disengaging of T-loop structure and, consequently, to
telomere deprotection, which may result in end-to-end
fusions and exonucleolytic attack [13, 21].
Several observations suggested a possible role for
RTEL1 during DNA replication. Mouse cells deficient
for RTEL1 exhibit reduced proliferative capacity, and
worms and mammalian cells lacking RTEL1 are particu-
larly sensitive to DNA damaging agents that hinder
DNA replication, such as inter-strand crosslinking
agents [13, 20, 22].
Wu et al. [12] showed that increased expression of
Rtel1 in mouse hepatocytes induced the development of
liver tumors. This finding is consistent with human gen-
etic data that showed that amplification of RTEL1 gen-
omic locus is not only a common genetic alteration in
human hepatocellular carcinoma, but also closely associ-
ated with its malignancy and progression [23–27].
In this study, we found for the first time recurrent
RTEL1 amplification statistically associated with advanced
age and intestinal type of gastric adenocarcinoma. Thus,
we suggest that amplification of RTEL1 may have age-
specific function and an important role in adenocar-
cinoma of intestinal type, which corroborates with the
hypothesis that these two histological types have different
genetic pathways [28, 29].
Consistent with these results, El-Rifai et al. [30] and
Kokkola et al. [31] found a significant association be-
tween 20q amplification and intestinal type of gastric
cancer. Interestingly, a molecular classification of gastric
cancer, proposed by Cancer Genome Atlas Research
Network [32], categorized intestinal gastric cancer as
correlated with chromosomal instability. Thus, RTEL1
may be a key gene of 20q region, since its upregulation
triggers chromosomal instability [13, 21].
Noteworthy, we observed that the frequency of RTEL1
amplification is almost equal in all stages of cancer (I-
41 %, II-30 %, III-44 % and IV-44 %), corroborating with
the hypothesis proposed by Tabach et al. [33] that ampli-
fication of the 20q chromosomal arm occurs early in
tumorigenic transformation and may initiate cancer.
The human ABC transporters are encoded by a large
transporter gene superfamily, which is composed of 49
members grouped into seven subfamilies (A–G) according
to the sequence homology. ABC proteins facilitate trans-
location of heterogeneous substrates including metabolic
products, lipids and sterols, peptides and proteins, saccha-
rides, amino acids and drugs across the cell membrane.
To transport these substrates across extracellular and
intracellular membranes against a concentration gradient,
ABCs use energy acquired by the hydrolysis of ATP [34].
Fig. 1 Copy number bar plot of RTEL1 gene showing high frequency of amplification in gastric adenocarcinoma samples
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ABCA13 is a member of ABC gene subfamily A
(ABCA) that plays a crucial role in the development of
resistance by the efflux of anticancer agents outside of
cancer cells [14] and overexpression of one or more
membrane-bound ATP-binding cassette (ABC) trans-
portes has been associated with such mechanism of drug
resistance [35].
There are few studies in literature regarding the role
of ABCA13 in cancer, but they demonstrate a positive
association between ABCA13 upregulation and unfavor-
able outcomes.
Upregulation of ABCA12, ABCA13, ABCB6, ABCC1,
ABCC2 and ABCE1 genes was found by Hlavata et al. [14]
in colorectal cancer samples when compared to normal
tissues and Nymoen et al. [15] observed that ABCA13
mRNA overexpression was significantly related to shorter
overall survival in metastatic ovarian serous carcinoma.
Importantly, Hlaváč et al. [16] stated that ABCA13,
ABCB3 and ABCC1 levels were significantly higher in
patients with grade 3 than in patients with grade 1 or 2
of breast carcinoma, suggesting that overexpression of
these genes may be associated with poor prognosis.
In the present study, we found for the first time recur-
rent amplification of ABCA13 statistically associated with
lymph node metastasis in gastric carcinogenesis. There-
fore, we suggest that amplification of ABCA13 gene has
an important role in development of lymph node metasta-
sis, which is associated with poor outcomes [36].
Moreover, we observed a significant association be-
tween ABCA13 amplification and male gender. In this
regard, it is important to note that ABC transporters can
move substrates in (influx) or out (efflux) of cells, such
as inorganic anions, metal ions and a large number of
hydrophobic compounds and metabolites across the
plasma membrane [37], which may include substances
that could be harmful to health. Since men are more ex-
posed to carcinogens than woman [38–43], the influx of
carcinogenic substances by ABCA13 channel could
Table 1 Clinicopathological data of patients with and without RTEL1 and ABCA13 amplification
RTEL1 CNV p-value ABCA13 CNV p-value RTEL1 and ABCA13 amplification p-value
≥3 copies Others ≥3 copies Others Present Absent
Gender
Male 32 53 0.987 38 42 0.003* 17 61 0.031*
Female 15 25 7 30 2 34
Age
≤50 years 8 27 0.034* 10 21 0.408 2 29 0.074
>50 years 39 51 35 51 17 66
Histopathology
Intestinal 36 46 0.045* 34 43 0.079 15 61 0.214
Diffuse 11 32 11 29 4 34
Localization
Cardia 12 12 0.197 9 15 0.901 4 19 0.969
Non-cardia 35 63 35 55 15 73
Stage
I–II 17 37 0.218 16 34 0.215 4 43 0.05*
III–IV 30 41 29 38 15 52
pN
N0 9 19 0.395 5 19 0.033* 2 23 0.157
N1 or more 37 53 39 48 17 67
pT
T1–T3 34 62 0.359 36 53 0.431 13 74 0.375
T4 13 16 9 19 6 21
pM
M0 10 15 0.746 10 13 0.741 4 17 0.360
M1 12 15 13 14 8 18
M male, F female, pN lymph node metastasis status, N0 without lymph node metastasis, N1 or more metastasis in one ore more lymph nodes, pT extent of the
primary tumor, T1–T3 without serosal extravasation, T4 with serosal extravasation, pM, distant metastasis status, M1 with distant metastasis, M0 without distant
metastasis. *Significant difference between groups with and without amplification, p ≤ 0.05, Chi-square test
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explain the high frequency of amplification of this gene
in male gender related to gastric cancer.
Conclusion
aCGH is a very useful tool for investigating novel genes
associated with carcinogenesis. Through this technique,
we were able to identify recurrent amplification of
RTEL1 and ABCA13 and this observation was validated
by real-time PCR for copy number analysis on a larger
number of samples and in other type of cancer, demon-
strating that these genes may have important roles in
the carcinogenesis process. Thus, RTEL1 amplification
may be important for the development of gastric cancer
in older patients, besides being a probable event contrib-
uting for chromosomal instability in intestinal gastric
carcinogenesis. Moreover, ABCA13 amplification may
have age-specific function and could be considered a
useful marker for predicting lymph node metastasis in
resected gastric cancer patients in early stage. Lastly,
RTEL1 and ABCA13 synergistic effect may be consid-




We analyzed gastric adenocarcinoma samples obtained
from primary gastric tumors of patients from João de
Barros Barreto University Hospital (HUJBB), located in
Pará State, Brazil.
All samples were obtained before administration of chem-
ical treatments or radiotherapy. This study was approved by
HUJBB ethics committee (CAAE: 42999115.7.0000.5634)
and all individuals signed a Consent Form allowing the use
of biological samples and clinical data.
For RTEL1 copy number investigation we used 125 fresh
frozen samples (Table 1), 68 % from male and 32 % from
female patients, with a mean age of 59 years (±13).
Regarding tumor site, 80 % were obtained from tumors
located outside from cardia region and 20 % of tumors
located in the cardia region. Of the total of samples, 57 %
were collected from patients with advanced stage (III and
IV) and 43 % from patients with early stage (I and II),
66 % of tumors belonging to the intestinal type and 34 %
to the diffuse type of Laurén. Also with respect to staging,
it was observed that 23 % of patients presented serosal ex-
travasation (T4), 76 % presented lymph node metastasis
and 52 % presented distant metastasis. For ABCA13 copy
number investigation we used 117 fresh frozen samples
(Table 1), because eight reactions were unsuccessful.
Additionally, we evaluated CNV status of these genes
in 47 oral squamous cell carcinoma samples, in an at-
tempt to investigate if the frequency of RTEL1 and
ABCA13 amplification is also high in other type of neo-
plasia. Sample composition was 64 % male and 36 % fe-
male patients, with a mean age of 61 years (±13).
Regarding tumor site, 80 % were obtained from tumors
located in tongue or floor of mouth. Of the total of sam-
ples, 56 % were collected from patients with advanced
stage (III and IV) and 44 % from patients with early
stage (I and II).
Histopathology
Tumor samples were included only if at least 80 % of
the sample consisted of cancer cells. Histopathological
Fig. 2 Copy number bar plot of ABCA13 gene showing high frequency of amplification in gastric adenocarcinoma samples
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data, such as histological subtype, degree of differenti-
ation, depth of invasion, lymph node involvement and
distant metastasis were taken from pathology reports of
the Department of Pathology of HUJBB. The histopatho-
logical analysis of tumor fragments was performed ac-
cording to Laurén’s classification [44].
Quantitative analysis of copy number variants based on
real-time PCR
Genomic DNA extraction was carried out using Gentra
Puregene Kit (Qiagen, Germantown, MD, USA), accord-
ing to the manufacturer’s instructions. After extraction,
we evaluated quantity and quality of each sample using
Nanodrop 1000 Spectophotometer (NanoDrop Tech-
nologies, Houston, TX, USA). The volume for each sam-
ple was adjusted accordingly to achieve 10 ng/μl using
nuclease free water.
We performed TaqMan Copy Number Assay (Applied
Biosystems, Foster City, CA). Briefly, 1 μl of 10 ng DNA
was added to 5 μL of TaqMan Genotyping Master Mix
(Applied Biosystems, Foster City, CA), with 0.5 μl of
RTEL1 or ABCA13 probe and 3 μL of water. We mea-
sured copy number gain using the following profile:
denaturation at 95 °C for 10 min, followed by 40 cycles of
95 °C for 15 s and 60 °C for 1 min. We determined relative
quantification using the 7500 Rreal-time PCR system
(Applied Biosystems, Foster City, CA) in quadruplicate.
RNaseP (Applied Biosystems, Foster City, CA) was used as
a control. After amplification, we imported the experiment
results containing threshold-cycle values for the copy
number and reference assay into the CopyCaller Software
(Applied Biosystems, Foster City, CA) for post-PCR data
analysis as previously described by Graziano et al. [45].
Statistics
Statistical analysis for comparisons of categorical vari-
ables between groups were done by means of Chi-square
test and were performed using PASW Statistics program.
Odds Ratio (OR) and Confidence Interval (CI = 95 %)
were also calculated. A two-tailed probability value p ≤
0.05 was considered to be statistically significant.
Abbreviations
ABC, ATP-binding cassette; ABCA12, ATP-Binding Cassette, Sub-Family A,
Member 12; ABCA13, ATP-Binding Cassette, Sub-Family A, Member 13; ABCB3,
ATP-Binding Cassette, Sub-Family B, Member 3; ABCB6, ATP-Binding Cassette,
Sub-Family B, Member 6; ABCC1, ATP-Binding Cassette, Sub-Family C, Member 1;
ABCC2, ATP-Binding Cassette, Sub-Family C, Member 2; ABCE1, ATP-Binding
Cassette, Sub-Family E, Member 1; aCGH, array Comparative Genomic
Hybridization; CNV, copy number variation; DSBs, Double Strand Breaks;
ERBB2, Erb-B2 Receptor Tyrosine Kinase 2; HER2, human epidermal growth
factor receptor 2; HR, homologous recombination; HUJBB, João de Barros
Barreto University Hospital; PCR, polymerase chain reaction; RTEL1, Regulator
of Telomere Length 1
Acknowledgements
We acknowledge Federal University of Pará (PROPESP and Fadesp) for
technical support and National Counsel of Technological and Scientific
Development and Coordination for Enhancement of Higher Education
Personnel for financial and fellowship support.
Funding
National Counsel of Technological and Scientific Development (CNPq), grant
n° 460185/2014-4, funded Copy Number Variation assays. Design of the
study, preparation of the manuscript and collection and interpretation of
data were not funded.
Availability of data and materials
The data will not be shared because some analyses of RTEL1 and ABCA13 genes
were carried out together with other data that have not yet been published.
Authors’ contributions
TA and AS performed the experiments. EL participated in the design of the
study and performed the statistical analysis. AK, RM and RB conceived of the
study, and participated in its design and coordination and helped to draft the
manuscript. PA was responsible for the surgeries. SD was responsible for
histopathological analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Ethics approval and consent to participate
João de Barros Barreto University Hospital ethics committee approved this
study (CAAE: 42999115.7.0000.5634). The patients consent to participate to
this study by signing a Consent Form allowing the use of biological samples
and clinical data. Moreover, we have obtained consent from the patients to
publish and to report individual data.
Author details
1Human Cytogenetics Laboratory, Federal University of Pará, Belém
66075-110, Pará, Brazil. 2Oncology Research Center, Federal University of Pará,
Belém 66073-000, Pará, Brazil. 3Molecular Biology Department, Federal
University of Paraíba, João Pessoa 58051-900, Paraíba, Brazil.
Received: 11 April 2016 Accepted: 23 June 2016
References
1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M,
Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and
Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International
Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Acessed 25
mar 2016.
2. INCA ‐ Instituto Nacional do Câncer. Estimativa 2016/2017- Incidência de
câncer no Brasil. http://www.inca.gov.br. Acessed 4 mar 2016.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin.
2011. doi:10.3322/caac.20107.
4. Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: progression in early
diagnosis and prognosis (Review). Oncol Lett. 2015;9(4):1502–8.
5. Wu HH, Lin WC, Tsai KW. Advances in molecular biomarkers for gastric
cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med.
2014. doi:10.1017/erm.2013.16.
6. Warneke VS, Behrens HM, Haag J, Balschun K, Böger C, Becker T, Ebert MP,
Lordick F, Röcken C. Prognostic and putative predictive biomarkers of
gastric cancer for personalized medicine. Diagn Mol Pathol. 2013. doi:10.
1097/PDM.0b013e318284188e.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick
F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J,
Kang YK, ToGA Trial Investigators. Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of HER2-positive
advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3,
open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
8. Buffart TE, Carvalho B, Mons T, Reis RM, Moutinho C, Silva P, van Grieken NC,
Vieth M, Stolte M, van de Velde CJ, Schrock E, Matthaei A, Ylstra B, Carneiro
F, Meijer GA. DNA copy number profiles of gastric cancer precursor lesions.
BMC Genomics. 2007;8:345.
Araújo et al. Molecular Cytogenetics  (2016) 9:52 Page 6 of 7
9. Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, Koo SH. Genetic
alterations in primary gastric carcinomas correlated with clinicopathological
variables by array comparative genomic hybridization. J Korean Med Sci.
2006;21:4.
10. Weiss MM, Kuipers EJ, Postma C, Snijders AM, Pinkel D, Meuwissen SG,
Albertson D, Meijer GA. Genomic alterations in primary gastric
adenocarcinomas correlate with clinicopathological characteristics and
survival. Cell Oncol. 2004;26(5–6):307–17.
11. Seabra AD, Araújo TM, Mello Junior FA, Di Felipe Ávila Alcântara D, De
Barros AP, De Assumpção PP, Montenegro RC, Guimarães AC, Demachki S,
Burbano RM, Khayat AS. High-density array comparative genomic
hybridization detects novel copy number alterations in gastric
adenocarcinoma. Anticancer Res. 2014;34(11):6405–15.
12. Wu X, Sandhu S, Nabi Z, Ding H. Generation of a mouse model for studying
the role of upregulated RTEL1 activity in tumorigenesis. Transgenic Res.
2012. doi:10.1007/s11248-011-9586-7.
13. Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O’Neil NJ, Petalcorin MI, Martin
JS, Collis SJ, Cantor SB, Auclair M, Tissenbaum H, West SC, Rose AM, Boulton
SJ. RTEL1 maintains genomic stability by suppressing homologous
recombination. Cell. 2008. doi:10.1016/j.cell.2008.08.016.
14. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak
P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka P, Soucek P. The role of
ABC transporters in progression and clinical outcome of colorectal cancer.
Mutagenesis. 2012;27(2):187–96.
15. Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B. CIAPIN1
and ABCA13 are markers of poor survival in metastatic ovarian serous
carcinoma. Mol Cancer. doi: 10.1186/s12943-015-0317-1.
16. Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V,
Koževnikovová R, Trnková M, Gatěk J, Kopperová D, Gut I, Souček P. The
expression profile of ATP-binding cassette transporter genes in breast
carcinoma. Pharmacogenomics. 2013;14(5):515–29.
17. Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY,
Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG. Copy number
analysis of ductal carcinoma in situ with and without recurrence. Mod
Pathol. 2015. doi:10.1038/modpathol.2015.75.
18. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider
A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Murty VV.
Identification of copy number gain and overexpressed genes on
chromosome arm 20q by an integrative genomic approach in cervical
cancer: potential role in progression. Genes Chromosomes Cancer. 2008.
doi:10.1002/gcc.20577.
19. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat
AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M. C-MYC locus
amplification as metastasis predictor in intestinal-type gastric
adenocarcinomas: CGH study in Brazil. Anticancer Res. 2006;26:4B.
20. Uringa EJ, Youds JL, Lisaingo K, Lansdorp PM, Boulton SJ. RTEL1: an essential
helicase for telomere maintenance and the regulation of homologous
recombination. Nucleic Acids Res. 2011. doi:10.1093/nar/gkq1045.
21. Bailey SM, Murnane JP. Telomeres, chromosome instability and cancer.
Nucleic Acids Res. 2006;34(8):2408–17.
22. Ding H, Schertzer M, Wu X, Gertsenstein M, Selig S, Kammori M, Pourvali R,
Poon S, Vulto I, Chavez E, Tam PP, Nagy A, Lansdorp PM. Niketeghad F,
Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP, Schirmacher P.
Regulation of murine telomere length by Rtel: an essential gene encoding a
helicase-like protein. Cell. 2004;117(7):873–86.
23. Taniguchi K, Yamada T, Sasaki Y, Kato K. Genetic and epigenetic
characteristics of human multiple hepatocellular carcinoma. BMC Cancer.
2010. doi:10.1186/1471-2407-10-530.
24. Katoh H, Shibata T, Kokubu A, Ojima H, Fukayama M, Kanai Y, Hirohashi S.
Epigenetic instability and chromosomal instability in hepatocellular
carcinoma. Am J Pathol. 2006. doi:10.2353/ajpath.2006.050989.
25. Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP,
Schirmacher P. Frequent genomic imbalances suggest commonly altered
tumour genes in human hepatocarcinogenesis. Br J Cancer. 2001;85(5):697–704.
26. Guan XY, Fang Y, Sham JS, Kwong DL, Zhang Y, Liang Q, Li H, Zhou H, Trent
JM. Recurrent chromosome alterations in hepatocellular carcinoma detected
by comparative genomic hybridization.Genes Chromosomes Cancer. 2000.
doi: 10.1002/1098-2264(2000)9999:9999<::AID-GCC1022>3.0.CO;2-V.
27. Wong N, Lai P, Lee SW, Fan S, Pang E, Liew CT, Sheng Z, Lau JW, Johnson PJ.
Assessment of genetic changes in hepatocellular carcinoma by comparative
genomic hybridization analysis: relationship to disease stage, tumor size, and
cirrhosis. Am J Pathol. 1999. doi:10.1016/S0002-9440(10)65248-0.
28. Tahara E. Genetic pathways of two types of gastric cancer. IARC Sci Publ.
2004;157:327–49.
29. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and
epigenetic alterations in multistep carcinogenesis of the stomach. J
Gastroenterol. 2000;35 Suppl 12:111–5.
30. El-Rifai W, Harper JC, Cummings OW, Hyytinen ER, Frierson Jr HF, Knuutila S,
Powell SM. Consistent genetic alterations in xenografts of proximal stomach
and gastro-esophageal junctionadenocarcinomas. Cancer Res. 1998;58(1):34–7.
31. Kokkola A, Monni O, Puolakkainen P, Larramendy ML, Victorzon M, Nordling
S, Haapiainen R, Kivilaakso E, Knuutila S. 17q12-21 amplicon, a novel
recurrent genetic change in intestinal type of gastric carcinoma: a
comparative genomic hybridization study. Genes Chromosomes Cancer.
1997;20(1):38–43.
32. Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of gastric adenocarcinoma. Nature. 2014. doi: 10.1038/
nature13480.
33. Tabach Y, Kogan-Sakin I, Buganim Y, Solomon H, Goldfinger N, Hovland R,
Ke XS, Oyan AM, Kalland KH, Rotter V, Domany E. Amplification of the 20q
chromosomal arm occurs early in tumorigenic transformation and may
initiate cancer. PLoS One. 2011. doi:10.1371/journal.pone.0014632.
34. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell
Biol. 1992;8:67–113.
35. Szakács G, Paterson JK, Ludwig JA, BoothGenthe C, Gottesman MM. Targeting
multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.
36. Deng JY, Liang H. Clinical significance of lymph node metastasis in gastric
cancer. World J Gastroenterol. 2014. doi:10.3748/wjg.v20.i14.3967.
37. Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC)
transporter Family. Hum Genomics. 2009. doi:10.1186/1479-7364-3-3-281.
38. Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR,
Schatzkin A. A prospective study of tobacco, alcohol, and the risk of esophageal
and gastric cancer subtypes. Am J Epidemiol. 2007;165(12):1424–33.
39. Kirsch-Volders M, Bonassi S, Herceg Z, Hirvonen A, Möller L, Phillips DH.
Gender-related differences in response to mutagens and carcinogens.
Mutagenesis. 2010. doi:10.1093/mutage/geq008.
40. Kadekar S, Peddada S, Silins I, French JE, Högberg J, Stenius U. Gender
differences in chemical carcinogenesis in National Toxicology Program
2-year bioassays. Toxicol Pathol. 2012. doi:10.1177/0192623312446527.
41. Saghier AA, Kabanja JH, Afreen S, Sagar M. Gastric cancer: environmental
risk factors, treatment and prevention. J Carcinogene Mutagene. 2013.
doi:10.4172/2157-2518.S14-008.
42. Cocco P, Ward MH, Buiatti E. Occupational risk factors for gastric cancer: an
overview. Epidemiol Rev. 1996;18(2):218–34.
43. Borugian MJ, Lee TK, Black P, Bressler B, Goldenberg SL, Gallagher R. Cancer
among males in BC and Canada. BCMJ. 2011;53(10):541–46.
44. Laurén P. The two histological main types of gastric carcinoma: diffuse and
so‐called intestinal‐type carcinoma. An attempt at a histo‐clinical
classification. Acta Pathol Microbiol Scand. 1965;64:31–49.
45. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D’Emidio S,
Catalano V, Sisti V, Ligorio C, Andreoni F, Rulli E, Di Oto E, Fiorentini G,
Zingaretti C, De Nictolis M, Cappuzzo F, Magnani M. Genetic activation of
the MET pathway and prognosis of patients with high-risk, radically
resected gastric cancer. J Clin Oncol. 2011. doi:10.1200/JCO.2011.36.7706.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Araújo et al. Molecular Cytogenetics  (2016) 9:52 Page 7 of 7
